What Makes AnaptysBio, Inc. (ANAB) a New Buy Stock
https://www.zacks.com/stock/news/2240910/what-makes-anaptysbio-inc-anab-a-new-buy-stock?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_12_zacks_rank_upgrade-2240910
Mar 14, 2024 - AnaptysBio, Inc. (ANAB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
0
AnaptysBio, Inc. (ANAB) Reports Q4 Loss, Tops Revenue Estimates
https://www.zacks.com/stock/news/2238869/anaptysbio-inc-anab-reports-q4-loss-tops-revenue-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-2238869
Mar 11, 2024 - AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of 8.62% and 174.29%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
0
Analysts Estimate Lexicon Pharmaceuticals (LXRX) to Report a Decline in Earnings: What to Look Out for
https://www.zacks.com/stock/news/2233958/analysts-estimate-lexicon-pharmaceuticals-lxrx-to-report-a-decline-in-earnings-what-to-look-out-for?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_9-2233958
Feb 29, 2024 - Lexicon (LXRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
0